CA3241217A1 - Composes heterocycliques en tant qu'agonistes polarises 5ht2a - Google Patents

Composes heterocycliques en tant qu'agonistes polarises 5ht2a Download PDF

Info

Publication number
CA3241217A1
CA3241217A1 CA3241217A CA3241217A CA3241217A1 CA 3241217 A1 CA3241217 A1 CA 3241217A1 CA 3241217 A CA3241217 A CA 3241217A CA 3241217 A CA3241217 A CA 3241217A CA 3241217 A1 CA3241217 A1 CA 3241217A1
Authority
CA
Canada
Prior art keywords
optionally substituted
alkyl
alkynyl
hydrogen
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3241217A
Other languages
English (en)
Inventor
Jian Jin
H. Umit KANISKAN
Ning Sun
Rehong SUN
Yan Xiong
Yudao SHEN
Zhongli XU
Xing Qiu
Jain Manish
Chao Qian
Samuel SLOCUM
Xiangyang Song
Georgios SKINIOTIS
Zhijie Deng
Ximena BARROS
Bryan Roth
Jeffrey DIBERTO
Kim KUGLAE
Carl-Mikael SUOMIVUORI
Marc A. DAEMGEN
Ron Dror
Brian Shoichet
Anat Levit KAPLAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Icahn School of Medicine at Mount Sinai
University of California San Diego UCSD
Leland Stanford Junior University
Original Assignee
University of North Carolina at Chapel Hill
Icahn School of Medicine at Mount Sinai
University of California San Diego UCSD
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill, Icahn School of Medicine at Mount Sinai, University of California San Diego UCSD, Leland Stanford Junior University filed Critical University of North Carolina at Chapel Hill
Publication of CA3241217A1 publication Critical patent/CA3241217A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Des composés qui sont des agonistes polarisés 5HT2A Gq et des méthodes d'utilisation de tels composés dans des maladies médiées par 5HT2A sont divulgués.
CA3241217A 2021-12-16 2022-12-16 Composes heterocycliques en tant qu'agonistes polarises 5ht2a Pending CA3241217A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163290602P 2021-12-16 2021-12-16
US63/290,602 2021-12-16
US202263407529P 2022-09-16 2022-09-16
US63/407,529 2022-09-16
PCT/US2022/053168 WO2023114472A1 (fr) 2021-12-16 2022-12-16 Composés hétérocycliques en tant qu'agonistes polarisés 5ht2a

Publications (1)

Publication Number Publication Date
CA3241217A1 true CA3241217A1 (fr) 2023-06-22

Family

ID=86773510

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3241217A Pending CA3241217A1 (fr) 2021-12-16 2022-12-16 Composes heterocycliques en tant qu'agonistes polarises 5ht2a

Country Status (4)

Country Link
EP (1) EP4447954A4 (fr)
AU (1) AU2022409512A1 (fr)
CA (1) CA3241217A1 (fr)
WO (1) WO2023114472A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018064465A1 (fr) 2016-09-29 2018-04-05 The Regents Of The University Of California Composés pour l'augmentation de la plasticité neuronale
CN113784962B (zh) 2019-02-27 2025-04-25 加利福尼亚大学董事会 用于治疗脑部疾病的氮杂环庚三烯并-吲哚类和其他杂环
TW202333668A (zh) 2021-12-15 2023-09-01 美商德利克斯醫療公司 經苯氧基及苄氧基取代之精神成形素(psychoplastogen)及其用途
IL326081A (en) * 2023-07-24 2026-03-01 Innovstone Therapeutics Ltd 5-HT2A receptor agonists, process for their preparation and uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9805716D0 (en) * 1998-03-17 1998-05-13 Merck Sharp & Dohme Therapeutic agents
ES2320955B1 (es) * 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
EP2464227A4 (fr) * 2009-08-10 2013-02-20 Galenea Corp Composés et leurs procédés d utilisation
WO2019149657A1 (fr) * 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Dérivés d'oxadiazolopyridine à substitution benzyle, (pyridin-3-yl)méthyle ou (pyridin-4-yl)méthyle utilisés en tant qu'inhibiteurs de la ghréline o-acyltransférase (goat)
EP4216949A4 (fr) * 2020-09-28 2024-12-11 Yale University Agonistes sélectifs du récepteur 5-ht2a et procédés d'utilisation
CN116917305A (zh) * 2020-12-07 2023-10-20 明德赛特制药公司 用于治疗cns病症的作为血清素能剂的3-环状胺-吲哚衍生物

Also Published As

Publication number Publication date
EP4447954A1 (fr) 2024-10-23
AU2022409512A1 (en) 2024-08-01
WO2023114472A1 (fr) 2023-06-22
EP4447954A4 (fr) 2025-12-03

Similar Documents

Publication Publication Date Title
CA3241217A1 (fr) Composes heterocycliques en tant qu&#39;agonistes polarises 5ht2a
KR102753101B1 (ko) 약제학적 화합물
EP3814360B1 (fr) Composés hétéroaryl pour traiter la maladie de huntington
KR102420938B1 (ko) Rock의 억제제로서의 스피로시클로헵탄
ES2855171T3 (es) Compuestos heterocíclicos bicíclicos y sus usos en terapia
CA2451678C (fr) Azaindoles
CA2833507A1 (fr) Derive d&#39;indazole et pyrrolopyridine et utilisation pharmaceutique de celui-ci
RU2548363C2 (ru) СЕЛЕКТИВНЫЕ ИНГИБИТОРЫ Haspin киназы
KR20180097749A (ko) Rock의 억제제로서의 스피로헵탄 살리실아미드 및 관련 화합물
TW200403243A (en) 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands
KR20210068422A (ko) 심장 근절 억제제
KR20220046592A (ko) 혈장 칼리크레인 저해제
BR112012009310B1 (pt) composto derivados de 2-oxo-1-pirrolidinil imidazotiadiazol, uso dos mesmos e composição farmacêutica compreendendo os mesmos
CA3223611A1 (fr) Modulateurs de la ferroptose, preparations et utilisations associees
TWI835009B (zh) 新穎化合物
KR20230015404A (ko) 무스카린성 아세틸콜린 수용체 m5의 경쟁적 억제제 및 비경쟁적 억제제
US20250129070A1 (en) Bifunctional androgen receptor compounds
WO2019012037A1 (fr) Dérivés de 1,3-diaza-spiro-[3.4]-octane
WO1998043976A1 (fr) Derives de biphenyle et compositions medicinales
TW202227404A (zh) 可用於治療與5-ht2a血清素受體相關疾病之作為5-ht2a血清素受體調節劑之異噁唑衍生物
TW202606669A (zh) Ａｒｎｔ降解化合物及其用途
CN120530098A (zh) 一类芳杂环化合物及其制备方法和应用
TW202241906A (zh) 吲唑化合物

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241209

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241209

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241209

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20250107